...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Prognostic Value of Serial Changes in High-Sensitivity Cardiac Troponin I and T over 3 Months Using Reference Change Values in Hemodialysis Patients
【24h】

Prognostic Value of Serial Changes in High-Sensitivity Cardiac Troponin I and T over 3 Months Using Reference Change Values in Hemodialysis Patients

机译:使用参考变化值在血液透析患者中​​连续3个月以上高敏性心肌肌钙蛋白I和T序列变化的预后价值

获取原文
           

摘要

INTRODUCTION: Serial changes in cardiac troponin in hemodialysis (HD) patients have uncertain clinical implications. We evaluated associations of adverse outcomes in HD patients with reference change value (RCV) data and tertile concentrations for cardiac troponin I (cTnI) and cTnT measured by high-sensitivity (hs) assays.METHODS: RCV data and tertiles for hs-cTnI and hs-cTnT were determined from plasma samples collected 3 months apart in 677 stable outpatient HD patients and assessed for their associations with adverse outcomes using adjusted Cox models. Primary outcomes were all-cause mortality and sudden cardiac death (SCD).RESULTS: During a median follow-up of 23 months, 18.6% of patients died. RCVs were: hs-cTnI +37% and ?30%; hs-cTnT +25% and ?20%. Patients with serial hs-cTnI and hs-cTnT changes RCV (increase or decrease) had all-cause mortality of 25.2% and 23.8% respectively, compared to 15.0% and 16.5% with changes ≤RCV [adjusted hazard ratios (aHRs): 1.9, P = 0.0003 and 1.7, P = 0.0066), respectively]. Only hs-cTnI changes RCV were predictive of SCD (aHR 2.6, P = 0.005). hs–Cardiac troponin changes RCV improved all-cause mortality prognostication compared to changes ≤RCV in tertile 2: hs-cTnI aHR, 2.70 ( P = 0.003); hs-cTnT aHR, 1.98 ( P = 0.043). The aHR of changes in hs-cTnI in tertile 2 RCV for SCD was 5.62 ( P = 0.039).CONCLUSIONS: Changes over 3 months in hs-cTnI and hs-cTnT of RCV identified patients at greater risk of all-cause mortality, and for hs-cTnI were also predictive of SCD. Among patients with middle tertile cardiac troponin concentrations, hs-cTnI changes RCV provided additive prognostic value for both SCD and all-cause mortality, whereas those for hs-cTnT provided additive prognostic value only for all-cause mortality.
机译:简介:血液透析(HD)患者心脏肌钙蛋白的系列变化具有不确定的临床意义。我们评估了HD患者的不良结局与参考变化值(RCV)数据和心肌钙蛋白I(cTnI)和cTnT的三分位数浓度(通过高敏(hs)测定法测量)的相关性。方法:RCV数据和hs-cTnI和三分位数从677名稳定的门诊HD患者中每3个月收集一次血浆样品中确定hs-cTnT,并使用调整后的Cox模型评估其与不良预后的关系。主要结果是全因死亡率和心源性猝死(SCD)。结果:在23个月的中位随访中,有18.6%的患者死亡。 RCV为:hs-cTnI + 37%和?30%; hs-cTnT + 25%和?20%。连续hs-cTnI和hs-cTnT变化> RCV(升高或降低)的患者的全因死亡率分别为25.2%和23.8%,而变化≤RCV的患者的全因死亡率则为15.0%和16.5%[校正的危险比(aHRs):分别为1.9,P = 0.0003和1.7,P = 0.0066)。仅hs-cTnI变化> RCV可以预测SCD(aHR 2.6,P = 0.005)。 hs –心肌肌钙蛋白变化> RCV与三分位数2≤RCV相比改善了全因死亡率的预后:hs-cTnI aHR,2.70(P = 0.003); hs-cTnT aHR,1.98(P = 0.043)。结论SCD患者三分位数2> RCV中hs-cTnI变化的aHR为5.62(P = 0.039)。结论:> RCV的hs-cTnI和hs-cTnT的变化超过3个月时,发现全因死亡的风险较高,而hs-cTnI也可预测SCD。在中三分之二心肌肌钙蛋白浓度的患者中,hs-cTnI变化> RCV可为SCD和全因死亡率提供相加的预后价值,而对hs-cTnT的患者仅能对全因死亡率提供相加的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号